RESUMO
In this final column by Paul Baldwin, there is discussion of the disease state specialties that pharmacists must be familiar with in their daily work. Chronic kidney disease (CKD), including end-stage renal disease (ESRD), has been the subject of much state and federal spending over several years. Government support has gone beyond health-program support and has extended to economic support as well.
Assuntos
Falência Renal Crônica , Insuficiência Renal Crônica , Humanos , Insuficiência Renal Crônica/terapia , Falência Renal Crônica/terapia , Governo , FarmacêuticosRESUMO
Although artificial intelligence (AI) has been around since the 1950s, it has become a phenomenon within the past couple of years, peaking in online search results in early 2023, following the release of OpenAI's ChatGPT. Inevitably, concerns began to surface over the impact that AI would have on jobs in an advanced economy like the United States.
Assuntos
Inteligência ArtificialRESUMO
Pharmacy Benefit Managers are pharmacy's favorite villains. These companies are notorious for their opaque practices and perceived focus on profits over patient care, at least in the eyes of those who are forced to deal with them every day.
Assuntos
Assistência Farmacêutica , Farmácias , Farmácia , HumanosRESUMO
The Pharmacy Benefit Management industry is one which seems to attract bipartisan scorn, similar to the pharmaceutical manufacturers. Despite widespread criticism for many years, the manufacturers were finally presented with a big setback with the passage of the Inflation Reduction Act, which included a provision to require price negotiation in Medicare for prescription drugs. The provision does not go into effect until 2026, giving manufacturers time to escape-if they are able.
